Literature DB >> 15047535

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.

Shazad Mushtaq1, Yigong Ge, David M Livermore.   

Abstract

Doripenem (S-4661), a new parenteral carbapenem, was tested against over 250 clinical isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp., selected or derived for their beta-lactamase expression characteristics. Imipenem, meropenem, and ertapenem were tested as comparators, along with cephalosporins and piperacillin-tazobactam, by using National Committee for Clinical Laboratory Standards agar dilution methodology. Doripenem MICs were from 0.03 to 0.25 microg/ml for Klebsiella isolates, irrespective of the presence of extended-spectrum beta-lactamases (ESBLs) or plasmid-mediated AmpC or hyperproduced K1 beta-lactamase. Similarly, MICs of doripenem for both AmpC-inducible and -derepressed Enterobacter isolates were 0.06 to 0.5 microg/ml. ESBL production did not raise the MICs of doripenem for Escherichia coli transconjugants, and studies with known expression mutants confirmed that neither inducible nor depressed AmpC beta-lactamase expression was protective in Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, or Morganella morganii. In all of these respects, doripenem resembled meropenem and imipenem, whereas the MICs of ertapenem were raised (but still < or =1 microg/ml) for many ESBL-producing klebsiellas and AmpC-derepressed E. cloacae and C. freundii strains. Resistance to all carbapenems, including doripenem (MICs of mostly 16 to 64 microg/ml, compared with 0.25 to 1 microg/ml for typical strains), was seen in Acinetobacter isolates with metallo-beta-lactamases or OXA-carbapenemases. Isolates of Klebsiella and Serratia spp. with IMP, KPC, and SME beta-lactamases also were resistant to doripenem (MICs, 8 to >64 microg/ml) and to other carbapenems, although the continued apparent susceptibility (MICs, < or =0.5 microg/ml) of E. coli derivatives with cloned IMP-1 and NMC-A beta-lactamases suggested that carbapenem resistance might require other factors besides the enzymes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047535      PMCID: PMC375315          DOI: 10.1128/AAC.48.4.1313-1319.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK.

Authors:  Luke Tysall; Mark W Stockdale; Paul R Chadwick; Marie-France I Palepou; Kevin J Towner; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

2.  Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.

Authors:  F Lopez-Otsoa; L Gallego; K J Towner; L Tysall; N Woodford; D M Livermore
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

3.  Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.

Authors:  M Afzal-Shah; N Woodford; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.

Authors:  D M Livermore; K J Oakton; M W Carter; M Warner
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998.

Authors:  G S Babini; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

6.  In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.

Authors:  H Mikamo; K Izumi; Y X Hua; Y Hayasaki; Y Sato; T Tamaya
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

7.  IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998.

Authors:  Y W Chu; M Afzal-Shah; E T Houang; M I Palepou; D J Lyon; N Woodford; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

Authors:  Caroline J Henwood; Tess Gatward; Marina Warner; Dorothy James; Mark W Stockdale; Richard P Spence; Kevin J Towner; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

9.  Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.

Authors:  Libera M Dalla-Costa; Juliana M Coelho; Helena A P H M Souza; Maria E S Castro; Christiane J N Stier; Karin L Bragagnolo; Alvaro Rea-Neto; Sergio R Penteado-Filho; David M Livermore; Neil Woodford
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Metallo-beta-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii.

Authors:  Jing-Jou Yan; Wen-Chien Ko; Chin-Luan Chuang; Jiunn-Jong Wu
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

View more
  21 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Authors:  Jimena Alba; Yoshikazu Ishii; Kenneth Thomson; Ellen Smith Moland; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Jiancheng Zhang; Sunil Maharjan; Michel Doumith; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

5.  Penetration of intact blood-brain barrier by doripenem.

Authors:  K Margetis; E Dimaraki; G Charkoftaki; E Vryonis; S Markantonis; N Boutos; H Archontaki; D E Sakas; G Valsami; A Skoutelis
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

6.  Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.

Authors:  Anne Marie Queenan; Wenchi Shang; Robert Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

7.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.